SPIRE HEALTHCARE GROUP PLC (SPI) — Investment Research Note

Executive summary

Spire is the UK's largest listed independent hospital operator, running 38 hospitals plus ~60 clinics serving PMI, self-pay and NHS patients. Over the 2020–2025 period, Spire has transitioned from a COVID-era NHS-cost-recovery contract to a private-mix–led model (private now ~70%+ of hospital revenue), with revenue growing from £920m (2020) to £1,511m (2024), Adjusted EBITDA from £161m to £260m, and net bank debt falling to £326m (2.0x covenant leverage). The single most important valuation point today is that Spire is in an "offer period" under the Takeover Code — Bridgepoint and Triton talks terminated in March 2026, but the Board remains in discussions with other parties, and the freehold estate (valued at >£1.4bn per the H1 25 disclosure vs. £953m market cap) provides material asset backing to any deal.

Fair value estimate

• Fair value range: 240 – 310p per share (implied market cap £961m – £1,242m)
• Methodology: primary — EV/EBITDA multiple applied to FY26 guided EBITDA of ~£270m; cross-checked against freehold NAV and precedent M&A price talk.
  • 5.0x – 6.0x EV/(post-IFRS 16) EBITDA on £270m gives EV of £1,350m–£1,620m. Less net bank debt of ~£356m (H1 25) = £994m–£1,264m equity. Per share: 248p–315p.
  • Cross-check: freehold estate £1.4bn; even after ~£375m bank debt and central overheads capitalised, the property alone approaches the current market cap. Ramsay Health Care's rejected 2021 bid was 240p — the current strategic-review process, if it produces a firm offer, would likely need to price above that in real terms.
• Vs current market cap £953.4m: mid-point (275p) implies +15.5% upside; range is roughly -0.4% to +30% 2026-05 trading update; 2025-07 H1; 2025-03 FY24; 2026-03-23 strategic review update.

Sector context

• Sector: Health Care — UK private hospitals, defensive services.
• Quality profile: Above sector on regulatory ratings (98% "Good"/"Outstanding"), roughly in line on margins (Adj EBITDA margin ~17%, targeting >21% medium-term for the Hospitals segment), above sector on leverage once IFRS 16 leases are included (£915m lease liabilities vs. £326m bank debt).
• Peers: HCA Healthcare (US-listed, much larger scale), Mediclinic (private), Ramsay Sante (Paris), plus private UK peers Circle Health, BMI/Nuffield. No perfect listed UK comparator.

Investment thesis

1. Structural private-healthcare tailwind + record NHS waiting lists. Self-pay revenue grew from £136m (2020) to £341m (2024), PMI from £338m to £664m; NHS commissioning has become the volatile top-up rather than the base 2025-03 FY24 results. Private now >70% of Hospital revenue vs. target 70–80%.
2. Freehold-backed strategic optionality. The Company has been in a Takeover Code offer period since September 2025; Bridgepoint/Triton dropped out but the Board is "in discussions with other parties" and freehold estate is disclosed at £1.4bn+ vs. current £953m market cap 2026-03-23 update; 2025-07 H1 CEO commentary.
3. £30m FY26 self-help savings on track plus £425m debt facility extended to 2028 — insulates the P&L from wage/NI cost pressure while margin expansion levers (Patient Support Centres, ~400 headcount reduction, digitalisation, higher-acuity mix) begin to compound 2025-12 trading update; 2026-05 AGM update.

Key risks

1. NHS commissioning cut-back and PMI tendering pressure. FY25 EBITDA came in at "around the bottom end" of the £270-285m guided range because of Integrated Care Board budget squeeze and proactive PMI tendering 2025-12-03 trading update. This is a structural, not one-off, headwind.
2. Wage inflation & NI/NMW absorption. FY26 faces c.£30m EBITDA headwind from NI/NMW, payor-mix changes and energy hedge roll-off; only c.£10m offsettable in-year via savings and price 2025-03 FY24 results.
3. Legacy Paterson liability and regulatory overhang — provision now largely used but £1.2m of legal fees still being incurred, and the sector's regulatory tolerance is low 2025-07 H1 25 note 21.

Operating leverage

Spire is a genuinely fixed-cost business: staff costs represent >40% of the cost base, property lease liabilities of £915m are inflation-linked and largely non-flexible, and depreciation is £108m. Gross margin is stable at 45–46%. Historically, revenue growth of ~6% (2024) delivered EBITDA growth of ~11%, suggesting an EBITDA operating leverage of roughly 1.8x. Management has quantified the medium-term target of >21% Hospital EBITDA margin (vs. 18.0% in FY24) which — on hospital revenue of ~£1.4bn — implies a further ~£40-50m EBITDA uplift from mix/efficiency alone. However, current spare capacity is limited (the Group is actively adding scanners and theatres) and PMI/NHS tariff renegotiation caps upside. Verdict: real operating leverage exists but is more "grind higher" than "explosive drop-through" — a 10-20% revenue surprise would likely add ~40-60% to EBIT, not multiples of it 2025-07 H1 25; 2025-03 FY24.

Value-trap signals

• Repeated near-guidance-bottom prints: FY25 EBITDA at bottom of £270-285m range; FY26 guided "broadly in line" — i.e. flat.
• NHS commissioning uncertainty is structural, not cyclical — the announced abolition of NHS England and ICB budget pressure means volume visibility is now weaker.
• High lease-adjusted leverage — £915m of RPI-indexed leases plus £377m bank debt on £270m EBITDA. Rate cover for covenant is 7.4x but sensitivity to any EBITDA decline is real.
• Offer period drag — the stock trades in a range with a "bid premium" that could evaporate if the strategic review concludes without a firm offer.

Earnings vs. expectations

• FY23: Beat — 232m EBITDA vs guidance range met, margin expansion delivered.
• FY24: Met — Adj EBITDA £260m in line with plan; revenue £1,511m (+11%).
• H1 25: Met — trading "in line with market expectations", £276m FY25 consensus reaffirmed at H1.
• FY25 (Dec 2025 trading update): Miss to the low end — Adj EBITDA expected "around the bottom end" of £270-285m range due to NHS commissioning slowdown. FY26 guided "broadly in line or slightly ahead" — later tightened to "broadly in line" (a subtle downgrade) at FY24 prelims and reaffirmed May 2026. Pattern: delivered against guidance for FY23-24 but the FY25 print skewed to the bottom of the range, and the FY26 profile is flat. This is a "meets-to-misses" trajectory, not a beats trajectory.

Conviction

3 — moderate.

• Anchors: (a) transparent financial disclosure with reconciliations for Comparable Basis metrics; (b) clean cash generation (94-95% conversion); (c) multiple valuation methodologies (EV/EBITDA, freehold NAV, precedent bid price) all point to a similar 240-320p range.
• Limits: (a) live strategic review means a firm offer could materially reshape the fair-value outcome in either direction; (b) NHS payor-mix uncertainty makes forward EBITDA more volatile than the "healthcare defensive" label suggests.